C. Difficile

The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.

Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.

A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.

Important factors to consider when selecting an appropriate therapy to treat C. difficile.

Implications regarding how to properly treat patients with C. difficile infections based on data that has emerged since clinical practice guidelines were last updated.

Recommendations for treating C. difficile upon a first recurrence as well as following multiple recurrences based on currently available treatment options and recommendations by the IDSA/SHEA clinical practice guidelines.

A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.

Types of testing algorithms used in clinical practice to help clarify a diagnosis of C. difficile infection.

Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.

A discussion regarding the increasing frequency of C. difficile recurrence and its effects on patients and the healthcare system.

Sources of transmission and challenges that impact the management of community-onset C. difficile.

What healthcare providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.

Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.

Biologics have become a novel treatment in recurrent C. difficile.

An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.

Clostridium difficile infection (CDI) was associated with poorer outcomes, including a higher risk of mortality, among patients with chronic pancreatitis, an evaluation of the Nationwide Inpatient Sample database found.

Genetic sequencing can help assess how patient gut flora compares to donor both before and after FMT, study finds.

Interestingly, infection rates of the bacterium have decreased in 2020.

Investigators reported that 2 formulations of their C.diff vaccine produced injection site reaction that forced stoppage of the studies.

An investigational vaccine for C difficile demonstrates multiyear efficacy in trials reported at 2020 IDWeek Conference.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

A third of patients hospitalized with community-onset Clostridioides difficile infections had recently been discharged from the same hospital, and most of those received antibiotics, according to research presented at IDWeek.

Invasive C glabrata found to be most prevalent strain of Candida in stool of patients with C difficile infection, and likely resistant to caspofungin.

An antiprotozoal used in veterinary medicine demonstrates potential for repurposing to replace metronidazole to treat Clostridioides difficile.

The 2-step algorithm for diagnosing Clostridioides difficile infection is difficult to interpret in patients who have cancer or are immunocompromised.

Administration of the investigational oral microbiome therapeutic SER-109 resulted in a statistically significant decrease in the proportion of patients who had C diff recurrence within 8 weeks of administration versus placebo.

Expansion of antimicrobial stewardship strategies to include vertical methods represents an opportunity for programs, both new and established, to further optimize antimicrobial use.

A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.